Scott Carollo, MD
Interventional Cardiology · Omaha, NENPI 1760459093
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Amgen at 56.6% of the total. Reporting peaked in 2023 at $9,666 and has fallen 97.8% since, to $214 in 2025.
Across 216 payments — averaging $87.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$11K
- Janssen Global Services, LLC$2K
- Medtronic$1K
- AstraZeneca$1K
- Boston Scientific$680
- Novartis$409
- plus $3K from 23 others
What the payments were for
- Consulting fees$2,06011%
- Speaking & faculty fees$8,05242%
- Travel & lodging$8384%
- Food & beverage$7,89642%
- Education$1071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 65 | $10,731 |
| Janssen Global Services, LLC | 1 | $1,575 |
| Medtronic(2 entities) | 7 | $1,244 |
| AstraZeneca | 24 | $1,028 |
| Boston Scientific | 7 | $680 |
| Novartis | 20 | $409 |
| Abbott | 5 | $406 |
| Shockwave Medical, Inc | 4 | $401 |
| Sanofi-aventis U.S. LLC | 15 | $342 |
| E.r. Squibb & Sons, L.L.C. | 7 | $323 |
| Saranas, Inc. | 3 | $321 |
| Edwards Lifesciences | 2 | $196 |
| Actelion Pharmaceuticals US, Inc. | 4 | $179 |
| ZOLL Circulation Inc | 2 | $135 |
| Pfizer | 8 | $127 |
| Teleflex LLC | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $119 |
| Boehringer Ingelheim | 7 | $101 |
| Johnson & Johnson | 5 | $82 |
| Chiesi USA, Inc. | 5 | $74 |
| Cardiovascular Systems Inc. | 2 | $65 |
| Philips North America LLC | 1 | $62 |
| Abiomed | 2 | $56 |
| Merck | 3 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Scpharmaceuticals Inc. | 2 | $30 |
| Kestra Medical Technology Services, Inc. | 2 | $30 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$9,587
- FARXIGA$602
- ONYX FRONTIER$304
- Resolute$275
- Vascular Lithotripsy$181
- RESOLUTE ONYX$165
- XIENCE SIERRA$146
- GENERAL - THERAPIES$146
- CAMZYOS$144
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$144
- AMPLATZER AMULET$134
- PRALUENT$125
- MANTA$125
- Temperature Management System$123
- Catheter$123
- Temperature Management System Start-Up Kit$123
- BRILINTA$123
- UPTRAVI$122
- OPSUMIT$122
- CROSSBOSS$116
How this compares
$18,952 in reported general payments places this provider in the 80th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $59,898 |
| XareltoRivaroxaban | 11 | $13,007 |
| Repatha SureclickEvolocumab | 14 | $12,153 |
| BrilintaTicagrelor | 14 | $9,638 |
| Atorvastatin Calcium | 88 | $1,004 |
| Ezetimibe | 33 | $720 |
| Propafenone Hcl | 12 | $531 |
| Carvedilol | 38 | $359 |
| Metoprolol Succinate | 32 | $332 |
| Lisinopril | 43 | $265 |
| Amlodipine Besylate | 30 | $257 |
| Potassium Chloride | 20 | $236 |
| Rosuvastatin Calcium | 13 | $182 |
| Amiodarone Hcl | 15 | $178 |
| ClopidogrelClopidogrel Bisulfate | 15 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $127 | $59,89856 claims |
| Johnson & JohnsonXarelto | $82 | $13,00711 claims |
| AstraZenecaBrilinta | $1,028 | $9,63814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Omaha
- Himanshu AgarwalOmaha$541K
- Poonam VelagapudiOmaha$142K
- Andrew GoldsweigOmaha$49K
- Jai ParekhOmaha$44K
- Shahbaz MalikOmaha$17K
- Toufik HaddadOmaha$14K
- Charles OlsonOmaha$12K
- Haysam AkkadOmaha$11K
- Ajaypaul SukhiOmaha$9K
- Filip OleszakOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.